# Phase II Trial of Lu-177 FAP-2286 in Patients With Carcinoma of Unknown Primary

> **NCT07434180** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Peter MacCallum Cancer Centre, Australia** · enrollment: 20 (estimated)

## Conditions studied

- Cancer of Unknown Primary

## Interventions

- **DRUG:** 177Lu-FAP-2286

## Key facts

- **NCT ID:** NCT07434180
- **Lead sponsor:** Peter MacCallum Cancer Centre, Australia
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06
- **Primary completion:** 2030-06
- **Final completion:** 2030-06
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2026-02-25

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07434180

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07434180, "Phase II Trial of Lu-177 FAP-2286 in Patients With Carcinoma of Unknown Primary". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT07434180. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*